COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value
Probably many people who watched or participated in the June 28 virtual US Food and Drug Administration (FDA) advisory committee meeting about updating COVID-19 vaccines could agree on 1 point, made by the agency’s Peter Marks, MD, Ph.D:
“It is science at its hardest.”
More
New Online
Views 8,944 Citations 0
25
Medical News & Perspectives
July 8, 2022
COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value
Rita Rubin, MA
Article Information
JAMA. Published online July 8, 2022. doi:10.1001/jama.2022.11252
related articles icon Related
Articles
Probably many people who watched or participated in the June 28 virtual US Food and Drug Administration (FDA) advisory committee meeting about updating COVID-19 vaccines could agree on 1 point, made by the agency’s Peter Marks, MD, PhD:
“It is science at its hardest.”
The SARS-CoV-2 Omicron variant is shown as green dots budding from a vero mammalian kidney epithelial cell 36 hours after infection.
The SARS-CoV-2 Omicron variant is shown as green dots budding from a vero mammalian kidney epithelial cell 36 hours after infection.
Steve Gschmeissner/sciencesource.com
The FDA convened its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss whether to add an Omicron component to boosters for the fall. In order to have enough doses by early October, “we will need to very rapidly move to let companies know what that selection will be,” Marks reminded the panelists. (How many doses will be enough isn’t clear—as of June 30, only 51.1% of fully vaccinated US adults aged 18 years or older had received 1 booster shot, while only 27% of fully vaccinated adults aged 50 years or older, for whom a second booster is recommended, had received 2, according to government data.)